Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia

  • Bolly, Hendrikus Masang Ban (Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Faried, Ahmad (Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Hermanto, Yulius (Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Lubis, Billy Parulian (Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Tjahjono, Firman Priguna (Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Hernowo, Bethy Suryawathy (Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital) ;
  • Arifin, Muhammad Zafrullah (Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital)
  • Received : 2020.03.09
  • Accepted : 2020.05.12
  • Published : 2021.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Diffuse astrocytic tumour (DAT) is a diffuse infiltrative astrocytoma tumour accompanied by molecular parameters such as the presence or absence of isocitrate dehydrogenase (IDH) gene mutations. Ki-67 is a marker for DAT proliferation, while programmed death ligand 1 (PD-L1) indicates an immune evasion mechanism. This study aimed to analyze the correlation among mutant IDH1 R132H, Ki-67, and PD-L1 immunoexpression in the DAT. Methods : A cross-sectional study was carried out on 30 paraffin blocks of DAT cases. Paraffin block samples consist of grade II (n=14), grade III (n=8), and grade IV (n=8). In this study, the immunohistochemistry-staining of mutant IDH1 R132H, Ki-67, and PD-L1 were carried out to determine the frequency of DAT with IDH1 mutations. Results : Our study shown the frequency of IDH1 mutations in grade II 50.0% (7/14), grade III 37.5% (3/8), and grade IV 12.5% (1/8). Our study also showed a difference in Ki-67 and PD-L1 expression between each the degree of DAT histopathology (p=0.0001 and p=0.002, respectively). There was an association between both mutant IDH1 R132H, and Ki-67 with PD-L1 expression in DAT (p=0.0087 and p=0.0049, respectively). Conclusion : DAT with the mutant IDH1 is frequently observed in grade II and small number of grade III. The expression of wild type IDH1, Ki-67, and PD-L1 were found to be higher in high grade DAT (grade III and grade IV). There is a correlation between each of mutant IDH1 status and Ki-67 with PD-L1 expression in DAT.

Keywords

References

  1. Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, et al. : Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol 19 : 1460-1468, 2017 https://doi.org/10.1093/neuonc/nox054
  2. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL : Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119 : 509-511, 2010 https://doi.org/10.1007/s00401-009-0632-y
  3. Chen RQ, Liu F, Qiu XY, Chen XQ : The prognostic and therapeutic value of PD-L1 in glioma. Front Pharmacol 9 : 1503, 2019 https://doi.org/10.3389/fphar.2018.01503
  4. Das B, Raj KV, Atla B : Clinicohistopathological study of astrocytomas along with Ki-67 proliferative index. Int J Res Med Sci 6 : 665-670, 2018 https://doi.org/10.18203/2320-6012.ijrms20180317
  5. Dwianingsih EK, Bawono RG, Rhamadianti AF, Bayuangga HF, Malueka RG : Correlation between grading and IDH1 mutation in Indonesian glioma. J Neurol Sci 381 : 386-387, 2017
  6. Faried A, Hermanto Y, Tjahjono FP, Valentino A, Arifin MZ : Identification of periostin as a potential biomarker in gliomas by database mining. World Neurosurg 135 : e137-e163, 2020 https://doi.org/10.1016/j.wneu.2019.11.077
  7. Fu J, Shu J, Yu X, Pan J, Lv G, Zhou S, et al. : Predicting tumor recurrence of astrocytoma by Ki-67 and proton magnetic resonance spectra. Int J Clin Exp Med 10 : 11187-11196, 2017
  8. Global Cancer Observatory : International Agency for Research on Cancer: Indonesia. Available at : https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
  9. Haah LE, Chong YG, Chu JW, Lee KC, Chae YS : Immunohistochemical study of gliomas using glial fibrillary acidic protein (GFAP), S-100 protein and neurofilament. J Korean Neurosurg Soc 20 : 389-398, 1991
  10. Iwai Y, Hamanishi J, Chamoto K, Honjo T : Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24 : 26, 2017 https://doi.org/10.1186/s12929-017-0329-9
  11. Kaminska B, Czapski B, Guzik R, Król SK, Gielniewski B : Consequences of IDH1/2 mutations in gliomas and an assessment of inhibitors targeting mutated IDH proteins. Molecules 24 : 968, 2019 https://doi.org/10.3390/molecules24050968
  12. Liu Y, Carlsson R, Ambjorn M, Hasan M, Badn W, Darabi A, et al. : PDL1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 33 : 14231-14245, 2013 https://doi.org/10.1523/JNEUROSCI.5812-12.2013
  13. Loenarz C, Schofield CJ : Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4 : 152-156, 2008 https://doi.org/10.1038/nchembio0308-152
  14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK : WHO Classification of Tumours of the Central Nervous System. 4th ed. Vol. 1. France : International Agency for Research on Cancer, 2016, pp15-76
  15. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 : 803-820, 2016 https://doi.org/10.1007/s00401-016-1545-1
  16. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H : IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15 : 6002-6007, 2009 https://doi.org/10.1158/1078-0432.CCR-09-0715
  17. Omer NS, Jalal JA, Ismael AT : IDH1 (R132H) imunoexpression in glioma. J Kurdistan Board of Med Specialities 4 : 57-63, 2018
  18. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. : The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16 : 896-913, 2014 https://doi.org/10.1093/neuonc/nou087
  19. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. : Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 : 84-88, 2007 https://doi.org/10.1038/nm1517
  20. Rover LK, Gevensleben H, Dietrich J, Bootz F, Landsberg J, Goltz D, et al. : PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) Mutations. EBioMedicine 28 : 97-104, 2018 https://doi.org/10.1016/j.ebiom.2018.01.016
  21. Saeed MS : IDH1 mutation in gliomas in Mosul city - Iraq. Open Access Maced J Med Sci 3 : 250-255, 2015 https://doi.org/10.3889/oamjms.2015.041
  22. Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, et al. : Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136 : 793-803, 2018 https://doi.org/10.1007/s00401-018-1905-0
  23. Sun X, Kaufman PD : Ki-67: more than a proliferation marker. Chromosoma 127 : 175-186, 2018 https://doi.org/10.1007/s00412-018-0659-8
  24. Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhagan A, Thennarasu K, et al. : IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol 138 : 177-184, 2012 https://doi.org/10.1309/AJCPZOIY3WY4KIKE
  25. Thotakura M, Tirumalasetti N, Krishna R : Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther 10 : 641-645, 2014 https://doi.org/10.4103/0973-1482.139154
  26. Turkalp Z, Karamchandani J, Das S : IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71 : 1319-1325, 2014 https://doi.org/10.1001/jamaneurol.2014.1205
  27. Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, et al. : The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res 35 : 86, 2016 https://doi.org/10.1186/s13046-016-0362-7
  28. Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. : Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology 5 : e1196310, 2016 https://doi.org/10.1080/2162402X.2016.1196310
  29. Xue S, Hu M, Li P, Ma J, Xie L, Teng F, et al. : Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 8 : 49702-49712, 2017 https://doi.org/10.18632/oncotarget.17922
  30. Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, et al. : IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget 6 : 30232-30238, 2015 https://doi.org/10.18632/oncotarget.4920